慢性间质性肾炎 中国就医指南

Chronic interstitial nephritis (CIN) is a progressive, immune-mediated or toxic-inflammatory disorder characterized by persistent inflammation and fibrosis of the renal interstitium—the supportive tissue surrounding the tubules—leading to gradual loss of kidney function. Unlike acute interstitial nephritis, which often presents with abrupt onset and reversible injury, CIN evolves insidiously over months to years, frequently remaining asymptomatic until significant renal impairment (e.g., reduced GFR, elevated serum creatinine) or structural damage (e.g., tubular atrophy, interstitial fibrosis on biopsy) becomes evident. Pathogenesis involves dysregulated T-cell–mediated immune responses, chronic exposure to nephrotoxic agents (e.g., NSAIDs, proton pump inhibitors, aristolochic acid in herbal remedies), autoimmune conditions (e.g., Sjögren’s syndrome, sarcoidosis), or recurrent infections. Genetic susceptibility (e.g., HLA variants) and epigenetic modifications may amplify inflammatory signaling pathways such as NF-κB and TGF-β, driving fibroblast activation and extracellular matrix deposition. Epidemiologically, CIN accounts for approximately 10–15% of all cases of chronic kidney disease (CKD) requiring renal biopsy in tertiary nephrology centers; its true prevalence is likely underestimated due to underdiagnosis—many patients are labeled broadly as having 'CKD of unknown origin.' Incidence rises with age, peaking in adults aged 50–70 years, and shows modest male predominance (M:F ≈ 1.3:1). Key risk factors include long-term NSAID or PPI use (>6 months), traditional herbal medicine ingestion (especially in East Asia), uncontrolled autoimmune disease, chronic urinary obstruction, and recurrent pyelonephritis. Importantly, environmental exposures—such as occupational solvents or heavy metals—and metabolic comorbidities (e.g., hyperuricemia, diabetes) synergistically accelerate interstitial damage. Quality of life is profoundly impacted: fatigue, nocturia, and cognitive fog commonly precede overt renal failure; as disease advances, patients experience progressive anemia, fluid retention, electrolyte imbalances, and increased cardiovascular morbidity. Psychological burden—including anxiety about dialysis dependency and employment limitations—is high, particularly among working-age adults. Early diagnosis via kidney biopsy remains the gold standard, though non-invasive biomarkers (e.g., urinary β2-microglobulin, NGAL, KIM-1) and advanced MRI techniques (e.g., diffusion-weighted imaging) are emerging to support timely intervention. Without targeted management, CIN progresses to end-stage kidney disease (ESKD) in ~25–40% of cases within 5–10 years, necessitating renal replacement therapy.

# 慢性间质性肾炎治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：eGFR ≥30 mL/min/1.73m²、无急性肾损伤、病因明确且可逆（如药物性、代谢性）者。

• •基础管理：停用肾毒性药物（NSAIDs、马兜铃酸类）、控制血压（ACEI/ARB）、限盐限蛋白（0.6–0.8 g/kg/d）

• •药物治疗（按档次）：

- 进阶档（进口ARB+活性维生素D+磷酸盐结合剂）：4800–9600元/年

• •检验监测：24h尿蛋白定量、β₂微球蛋白、肾小管功能（尿NAG酶）、肾脏超声，单次检查费1200–2000元

二、介入/核心治疗方案

本病无根治性手术指征；肾活检为唯一有创诊断手段，非治疗性，仅用于病因不明或快速进展者。

• •经皮肾穿刺活检（B超引导）：

- 全套费用（含术前凝血四项、术后卧床监护、病理免疫组化）：4800–7200元

三、晚期/并发症/耐药方案

• •CKD 4–5期合并贫血/矿物质骨病：静脉铁剂+罗沙司他+拟钙剂，年均费用1.8–3.5万元
• •终末期需替代治疗：血液透析（医保后自付约300–800元/次，年均3–6万元）；腹膜透析置管+耗材年均4.2–6.5万元；肾移植术前评估+等待期管理2.5–4万元（不含移植手术费）

四、方案快速选择指南

• •预算有限/早期患者：首选国产药物+规律随访（年支出≤3000元）
• •中高收入/进展风险高者：进阶药物+年度肾活检评估（年支出1.2–1.8万元）
• •eGFR＜15或反复并发症者：启动透析准备及多学科评估（年支出≥4万元）